Sermorelin and tesamorelin are both derived from the growth hormone-releasing hormone (GHRH) sequence [2,6]. Ipamorelin is not derived from GHRH and acts through a different receptor system [7]. Treating the three as one class without that distinction can obscure the interpretation of published results.
The compounds are grouped here by receptor, because receptor identity is a main variable in interpreting a comparison. The origin of the parent molecule is described first.
One hormone, two derivatives, one unrelated peptide
In 1982, Guillemin and colleagues reported a 44 amino acid peptide with growth hormone-releasing activity, isolated from a human pancreatic tumor that had caused acromegaly [1]. The synthetic replicate had biological activity in vitro and in vivo. At that time, the hypothalamic factor remained uncharacterized: the paper described matching biological activity, not an established sequence identity with hypothalamic GHRH [1].
Later work established that the sequence isolated from human hypothalamic tissue was identical to the tumor-derived sequence [10]. GHRH is also written GRF. The 44 residue sequence opens Tyr-Ala-Asp-Ala-Ile-Phe [1,10]. Sermorelin and tesamorelin are derivatives of that sequence; ipamorelin is not [2,6,7].
Sermorelin: the 29 residue fragment
Sermorelin is the amidated N-terminal fragment GHRH(1-29)NH2. This sequence was used as the native reference peptide in a pig study comparing two GRF analogues [2]. It is a fragment of the longer GHRH molecule, not a different receptor class.
The distinction between potency and maximal response matters here. In a primary structure-activity study using rat anterior pituitary cells, the amidated 29, 30 and 31 residue fragments retained about half the relative potency of the parent hGRF under the reported assay conditions [3]. Shorter fragments could retain full intrinsic activity despite much lower potency. Thus, activity of the 29 residue fragment does not establish identical potency across species or assays, or make it the shortest active fragment [3].
Plasma stability is another part of the comparison. Frohman and colleagues studied human GHRH(1-44)NH2 in human plasma in vitro using high-performance liquid chromatography (HPLC) [4]. The intact peptide had a reported disappearance half-life of 17 minutes. The main degradation fragment, GHRH(3-44)NH2, retained less than 0.1% of the original biological activity [4]. Total immunoreactivity persisted longer, illustrating why the analytical endpoint matters.
Those measurements describe GHRH(1-44)NH2. They are not a half-life measurement for sermorelin. A later study found that GHRH(1-29)NH2 was also rapidly cleaved at the bond between residues 2 and 3 in plasma [5]. A sermorelin half-life cannot simply be taken from the longer peptide.
In 1989, the enzyme responsible for this main cleavage was characterized as dipeptidylpeptidase IV (DPP-IV) [5]. Removal of the two N-terminal residues gives GHRH(3-44)NH2 from the 44 residue substrate. D-amino acid substitution at position 1 or 2 prevented that hydrolysis in the tested analogues [5]. Tesamorelin addresses this cleavage with an N-terminal modification rather than a D-amino acid substitution [6].
Tesamorelin: GHRH with an N-terminal modification
Tesamorelin is human GHRH(1-44)NH2 carrying a single added group at the N-terminus [6]. Its development name was TH9507, and the modification is a trans-3-hexenoyl group attached to Tyr1 [6].
The nonclinical TH9507 study examined plasma stability and elimination. The modification conferred resistance to DPP-IV deactivation and slowed degradation in rat, dog and human plasma in vitro [6]. In dogs, the apparent elimination half-life of immunoreactive TH9507 was 21 to 45 minutes [6]. This is an animal measurement of immunoreactive material, not a human half-life or a direct measurement of intact peptide by the same method used in the earlier GHRH study.
Sermorelin and tesamorelin belong to the GHRH-derived group, but they are not identical backbone controls [2,6]. Sermorelin contains 29 residues; tesamorelin retains the 44 residue sequence with an N-terminal modification. Both sequence length and terminal chemistry differ. The dog elimination result cannot, on its own, quantify the effect of the terminal group in a matched comparison with sermorelin.
Ipamorelin: a different receptor system
Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, in which Aib is 2-aminoisobutyric acid and D-2-Nal is D-2-naphthylalanine [7]. Antagonist profiling placed its growth hormone (GH) response at a GHRP-like receptor, rather than the GHRH receptor [7]. This receptor system corresponds to the growth hormone secretagogue receptor cloned in 1996 [8], now commonly called the ghrelin receptor, GHS-R1a, after ghrelin was identified as its natural ligand in 1999 [9]. The antagonist experiment was functional pharmacology, not a direct binding-affinity measurement at a cloned receptor.
A comparison of sermorelin or tesamorelin with ipamorelin therefore involves two receptor systems, not three compounds acting at one receptor [2,6,7,8,9].
Raun and colleagues measured GH release in primary rat pituitary cells. Ipamorelin and GHRP-6 had EC50 values of 1.3 and 2.2 nmol/L, respectively [7]. These are concentrations for a functional response, not binding constants. In swine, the investigators also measured ACTH and cortisol responses. With ipamorelin, these were not significantly different from the responses observed with GHRH under the tested conditions [7]. These observations describe the rat-cell assay and swine model, not a general endocrine or safety profile.
Side by side
| Feature | Sermorelin | Tesamorelin | Ipamorelin |
|---|---|---|---|
| Sequence basis | GHRH(1-29)NH2 [2]. | Human GHRH(1-44)NH2 with a trans-3-hexenoyl group on Tyr1 [6]. | Not derived from GHRH; identified in a series lacking the central Ala-Trp pair of GHRP-1 [7]. |
| Receptor grouping | GHRH-derived peptide [2]. | GHRH-derived analogue [6]. | GHRP-like receptor in antagonist profiling; the GHS receptor system [7,8,9]. |
| Structural distinction | Amidated 29 residue fragment; potency depends on assay context [3]. | N-terminal acyl modification; DPP-IV resistance in the reported study [6]. | Pentapeptide with a different sequence and receptor system [7]. |
| Stability or elimination evidence | Rapid cleavage of GHRH(1-29)NH2 in plasma; no numerical half-life assigned here [5]. | Apparent elimination half-life of immunoreactive TH9507: 21 to 45 minutes in dogs [6]. | No numerical half-life supplied by the cited pharmacology abstract [7]. |
| Separate endocrine observation | No matched comparison reported here. | No matched comparison reported here. | ACTH and cortisol responses in swine were not significantly different from GHRH responses in the tested conditions [7]. |
Interpreting the comparison
Several differences are present at once. In the sermorelin and tesamorelin comparison, DPP-IV susceptibility is one variable and chain length is another [5,6]. The published studies also used different analytical endpoints. Intact-peptide disappearance, total immunoreactivity and apparent in vivo elimination are not interchangeable measurements [4,6].
Ipamorelin adds a second receptor system. The antagonist controls in its original pharmacology study are part of the evidence for that distinction [7]. Separate receptor readouts and the species and assay conditions remain essential context when comparing results. None of these papers supplies a single matched experiment ranking all three compounds.
References
- Guillemin R, et al. Science. 1982;218(4572):585-587. DOI: 10.1126/science.6812220. PMID: 6812220.
- Dubreuil P, et al. Growth Horm IGF Res. 2001;11(3):173-186. DOI: 10.1054/ghir.2001.0150. PMID: 11735232.
- Ling N, et al. Biochem Biophys Res Commun. 1984;123(3):854-861. DOI: 10.1016/0006-291X(84)90309-7. PMID: 6435620.
- Frohman LA, et al. J Clin Invest. 1986;78(4):906-913. DOI: 10.1172/JCI112679. PMID: 3093533.
- Frohman LA, et al. J Clin Invest. 1989;83(5):1533-1540. DOI: 10.1172/JCI114049. PMID: 2565342.
- Ferdinandi ES, et al. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. DOI: 10.1111/j.1742-7843.2007.00008.x. PMID: 17214611.
- Raun K, et al. Eur J Endocrinol. 1998;139(5):552-561. DOI: 10.1530/eje.0.1390552. PMID: 9849822.
- Howard AD, et al. Science. 1996;273(5277):974-977. DOI: 10.1126/science.273.5277.974. PMID: 8688086.
- Kojima M, et al. Nature. 1999;402(6762):656-660. DOI: 10.1038/45230. PMID: 10604470.
- Ling N, et al. Proc Natl Acad Sci USA. 1984;81(14):4302-4306. DOI: 10.1073/pnas.81.14.4302. PMID: 6431406.
This content is intended for research purposes only and is not meant to constitute medical advice. Not for human or veterinary use.
This educational material discusses laboratory research concepts only. Loti Labs products are intended strictly for research and development use and are not for human consumption.